Research

Macro partitioning

Body composition-targeted agents (e.g., bimagrumab) preserve or increase lean mass while reducing fat mass, addressing the functional decline associated with rapid weight loss.

If you are concerned about losing muscle while losing weight, ask your doctor about body composition-targeted therapies. Drugs like bimagrumab are designed to burn fat while building or preserving muscle, which helps maintain strength and function.

ModerateSupportsMEDIUM confidence
The most notable is bimagrumab, an activin type II receptor antagonist that selectively reduces fat mass while increasing lean mass... In phase 2 trials, bimagrumab produced a modest, up to 6.5% weight loss, 20.5% reduction in fat mass alongside a 3.6% increase in lean mass over 48 weeks
Ioannis Lempesis et al. · Metabolism Open · 2026

Why this rating

Based on Phase 2 trials.

Source

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies

Ioannis Lempesis et al. · Metabolism Open · 2026

DOI 10.1016/j.metop.2026.100463

narrative_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →